Jackson Center, PA, September 27, 2022 – Halberd Corporation (OTC-PINK: “HALB”) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a wholly owned subsidiary of Halberd Corporation named “ExtendalifeTM”. The mission will be to develop treatments intended to increase longevity and develop successful Alzheimer’s Disease and Cancer treatments using the combined patented and patent-pending technologies of the alliance member companies. The subsidiary will be staffed by personnel from all three entities for the purpose of developing and combining Halberd’s patented extracorporeal technology for the elimination of target disease antigens with AI Longevity’s work to date which has identified several bio-factors, markers and antigens which contribute to aging, with Stem of Hope’s stem cell research in disease treatment.
Gabe Vlad, AI Longevity, Inc.’s CEO, is in the process of developing a Longevity Index App (the “LIA”) and has identified numerous factors, including antigens, associated with the aging process which could be factored into the algorithms associated with a personalized assessment with regard to aging, longevity and quality of life of the user, and provide suggestions and methods to enhance same. Stem of Hope will lead the research with regard to the use of stem cells in support of longevity enhancement and Cancer treatments
“We plan to commence animal testing prior to the end of the year,” explained Mitchell Felder, M.D., Halberd’s Chief Technology Officer and a board-certified attending neurologist. “The anti-aging products developed by our partner and our extracorporeal technology, are expected to remove harmful age and inflammatory cytokines/antigens from the blood of small animals and allow the team to reassess the animal’s longevity. In several months we expect to have some early indications of the feasibility of our technology in improving longevity.”
“Longevity is not just living longer,” Dr. Felder further explained, “it involves quality of life as well. In the upcoming weeks, we will highlight our partners’ products which will be utilized conjunctively with our extracorporeal technology to improve both longevity and quality of life. We also feel strongly that Cancer prevention, and/or treatment will be an important by-product of this therapy, given the commonality of some of the bio factors and applicable methodology.”
Dr. Mitchell S. Felder, together with Mr. Gabriel Vlad, an aerospace engineer and inventor, will direct the research and jointly serve as Chief Technology Officers for the subsidiary. William A. Hartman, Chairman, President & CEO of Halberd Corporation, will serve as the subsidiary’s President and CEO.
The mission of the subsidiary will be to:
- Demonstrate longevity index improvement with the utilization of specific patent-pending products and Halberd’s extracorporeal technology to enhance the efficacy.
- Initiate a clinic model for longevity that will be affordable and effective.
Halberd intends to ultimately commence the process to spin off ExtendalifeTM as a separate publicly traded company. Halberd shareholders and warrant holders will receive shares in the spin-off company along with options and warrants to purchase additional shares. This process will be expedited since Halberd is now a fully reporting company with Public Company Accounting Oversight Board (PCAOB) audits complete.
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated, “Formation of this subsidiary is focused on the use of Halberd’s patented extracorporeal technology to eradicate the pathophysiologic basis or cause of Alzheimer’s Disease and Cancer from bodily fluids in conjunction with complementary technologies that will be disclosed as data develops. This is just the first of many anticipated specialty-focused applications of Halberd’s technology. We believe Halberd will be able to prevent other diseases besides Alzheimer’s Disease and Cancer through early detection and eradication of the disease basis before it can manifest itself in the patient. We belive this is an important first in medicine and serves an unfulfilled need that will improve quality of life and increase longevity.”
To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation.
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.